Carla Nasca, Ph.D., is a post-doctoral fellow of the American Foundation for Suicide Prevention in the laboratory of Neuroendocrinology at the Rockefeller University, New York. Dr. Nasca received her B.A. in Molecular Biology and her M.S. in Electrophysiology from the University of Palermo in Italy. She earned her Ph.D. in Neurobiology and Pharmacology from the University Sapienza in Rome, Italy, before moving to The Rockefeller University under the mentorship of Dr. Bruce McEwen.
Dr. Nasca is interested in novel rapidly acting therapeutic strategies to overcome the slow responses and treatment resistance of common drugs by understanding the epigenetic factors involved in inherent individual susceptibility to mood disorders, such as depression and anxiety. In particular, her Ph.D. thesis led to the discovery of the novel antidepressant candidate, acetyl-L-carnitine that laid the groundwork for her current work.
Dr. Nasca is recipient of a number of awards and recognition for her work, including a fellowship from American Foundation for Suicide Prevention, and others from the European Society of Neuropsychopharmacology, the Sackler Institute and Robertson Therapeutic Foundation and the 2013 Best Ph.D. Thesis Award from Academia Gioenia.
Grants and Funding: We proudly support the research and programs of 501(c)(3) non-profit organizations and institutions such as: the Anxiety Disorders program of the Jane & Terry Semel Institute for Neuroscience & Human Behavior at the University of California, Los Angeles; the Pacific Institute of Medical Research; the International Foundation for Research and Education on Depression (iFred); and SchoolsForHope.org, an iFred educational project. Working with these partners enables Anxiety.org to extend its commitment to its mission. All the donations received, as well as 100% of Anxiety.org revenue in 2019, will be contributed to build, develop, and further the understanding, investigation, discovery, and treatment of the full spectrum of anxiety and related disorders.